Last reviewed · How we verify

NCT05689749: SMI

Superb Microvascular Imaging Ultrasonography of Lacrimal Gland in Patients With Sjögren Syndrome

Completed Last updated 26 June 2023
What this trial tests

trial testing Superb Microvascular Imaging (SMI) (Toshiba) in Inflammation in 42 participants. Completed in 1 June 2023.

Timeline
1 April 2021
Primary endpoint
3 January 2023
1 June 2023

Quick facts

Lead sponsorNigde Omer Halisdemir University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment42
Start date1 April 2021
Primary completion3 January 2023
Estimated completion1 June 2023
Sites1 location across Turkey (Türkiye)

Drugs / interventions tested

Conditions studied

Sponsor

Nigde Omer Halisdemir University

Who can join

Adults 18 to 65, any sex, with Inflammation or Sjogren's Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A prospective study will be conducted to evaluate inflammatory activity in lacrimal glands due to Sjögren's syndrome on Superb Microvascular Imaging (SMI), gray scale ultrasound (US), color Doppler US and Power Doppler US.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Superb Microvascular Imaging (SMI) (Toshiba)

Trials testing the same drug.

Other recruiting trials for Inflammation

Currently open trials in the same condition.

Other Nigde Omer Halisdemir University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05689749.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing